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Risk Factors for Occurrence and 30-Day Mortality for 
Carbapenem-Resistant Acinetobacter baumannii Bacteremia 
in an Intensive Care Unit
To assess the risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) 
bacteremia and for 30-day mortality in patients with CRAB bacteremia in the intensive 
care unit (ICU), we conducted a retrospective study in the ICU at Severance Hospital in 
Korea from January 2008 to December 2009. Patients who acquired CRAB bacteremia in 
the ICU were enrolled as the case group and patients whose specimens of blood culture, 
sputum/endotracheal aspirate and urine revealed no AB were enrolled as controls. The case 
group comprised 106 patients and 205 patients were included as controls. Risk factors 
independently associated with CRAB bacteremia included prior chemotherapy or 
radiotherapy treatment (Odds ratio [OR], 3.6; P = 0.003), recent central venous catheter 
insertion (OR, 5.7; P < 0.001) or abdominal drainage insertion (OR, 21.9; P = 0.004), the 
number of antibiotics treated with (OR, 1.3; P = 0.016), and respiratory failure in the ICU 
(OR, 2.5; P = 0.035). The 30-day mortality was 79.8%. Renal failure during ICU stay was 
independently associated with 30-day mortality (OR, 3.7; P = 0.047). It is important to 
minimize invasive procedures, and to restrict excessive use of antibiotics, especially in 
immunocompromised patients, in order to prevent the development of CRAB bacteremia. 
Greater concern for CRAB bacteremia patients is needed when renal failure develops during 
ICU stay.
Key Words: Drug Resistance, Multiple; Acinetobacter baumannii; Risk Factors; Mortality; 
Bacteremia; Intensive Care Units
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INTRODUCTION
Acinetobacter baumannii (AB), a non-fermenting Gram-nega-
tive aerobic coccobacillus, has emerged worldwide as an impor-
tant nosocomial pathogen. Previously regarded as an organism 
of questionable pathogenicity, it has been considered as patho-
gen that causes life-threatening hospital acquired infections, 
particularly in intensive care units (ICU) (1-3). 
 Presently, AB has become a great concern because it is de-
tected frequently as a multiple or extreme drug-resistant bacte-
ria (4-6). Carbapenems are the antimicrobial agents of choice 
for treatment of serious infections due to multidrug resistant 
AB (7, 8). Unfortunately, the number of carbapenem-resistant 
AB (CRAB) isolates discovered has increased in recent years (1, 
7, 9-11), which is problematic becauses carbapenem-resistance 
limits clinician’s options for successful treatment and leads to 
an increased mortality (7, 12). 
 Among the extensive range of infections caused by CRAB, 
bacteremia is of particular concern because it contributes to 
high mortality and has been shown to be associated with ICU 
stay (13-16). Previous studies have demonstrated risk factors 
related to CRAB infection as well as to mortality due to CRAB (4, 
9, 17-20). However, limited data focusing on both risk factors 
for CRAB bacteremia and mortality due to CRAB bacteremia 
exist presently. 
 Therefore, the aim of this study was to investigate both risk 
factors for CRAB bacteremia and for 30-day mortality in pa-
tients with CRAB bacteremia. Also, we attempted to analyze an-
tibiotic usage and antimicrobial susceptibility patterns of CRAB 
in CRAB bacteremia patients. 
 
MATERIALS AND METHODS
Setting
This study was conducted at the Severance Hospital, in Seoul, 
Korea (a university, tertiary, referral hospital), which has around 
2000 beds, including 117 beds in the ICU. Our study was per-
formed retrospectively. The subjects were adults (aged ≥ 18 yr) 
admitted to the medical ICU equipped with 30 beds during the 
period from January 2008 to December 2009. We performed 
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screening cultures of blood, urine, and endotracheal aspirate/
sputum in all the patients upon ICU admission. We also per-
formed additional cultures when systemic inflammatory re-
sponse syndrome was newly observed or persisted for more 
than 3 days despite a change in antibiotics administered, or 
when a patient’s clinical condition had deteriorated, including 
worsening of respiratory status, requiring mechanical ventila-
tion, vasopressors, or massive fluid resuscitation. We defined 
colonization as the presence of AB in sputum/endotracheal as-
pirate, urine or secretion which did not cause adverse clinical 
symptoms or signs, according to the surveillance definitions of 
the Centers for Disease Control and Prevention/National Health-
care Safety Network (21). In order to exclude the effects of ex-
posure to external influences before admission to the ICU, we 
excluded patients who died within 48 hr of admission to the 
ICU. As some previous studies reported a significant increase in 
the incidence of bacteremia in patients with AB colonization 
(22), we excluded patients who were previously colonized with 
AB in order to eliminate the influence of this factor as much as 
possible. 
Case group 
The case group was defined as patients with ICU-acquired CRAB 
bacteremia. ICU-acquired CRAB bacteremia was defined as the 
identification of one or more CRAB from blood cultures obtained 
48 hr after admission to the ICU with systemic inflammatory 
response syndrome (SIRS) (23-26). The first isolation of CRAB 
was considered. When AB bacteremia was identified, we admin-
istered the following antibiotics, including ampicillin-sulbac-
tam, amikacin or carbapenem, until the results of antimicrobial 
susceptibility tests were reported. And we changed the admin-
istration of antibiotics according to the results of the antimicro-
bial susceptibility tests.
Control group
The control group was comprised of patients who had been ad-
mitted to the ICU during the same study period and in whom 
AB had never been isolated from blood specimens, sputum spec-
imens/endotracheal aspirates, and urine specimens. 
Definitions
Patients with infection or colonization were assessed following 
the definition proposed by the Centers for Diseases Control and 
Prevention (CDC) (23). The microorganisms were defined as 
CRAB if AB with minimum inhibitory concentrations (MICs) of 
≥ 8 µg/mL for both imipenem and meropenem were recorded. 
AB that was susceptible to meropenem but was resistant to imi-
penem, or susceptible to imipenem but resistant to meropen-
em was excluded from the analysis to alleviate confusion. Anti-
biotic sensitivity was determined by the disc diffusion method 
according to the guidelines of the Clinical and Laboratory Stan-
dards Institute (CLSI) (27).
 The baseline dates were defined as the day that CRAB was 
identified in the case group, and the day of discharge from ICU 
in the control group. The reason for these definitions for the base-
line dates was that CRAB bacteremia occurred in the case group 
patients because they were exposed to a risk factor, and the con-
trol group patients, who were not exposed to any risk factors, 
were discharged from ICU without CRAB infection (22).
 Possible risk factors investigated prior to admission to the ICU 
included the following: age, sex, APACHE II score, presence of 
shock at admission to ICU, stay in the general ward before ad-
mission to ICU, underlying diseases and the causes of ICU ad-
mission. Possible risk factors investigated after admission to ICU 
included the following: stay in ICU until the baseline date, total 
parenteral nutrition, presence of immunosuppression, neutro-
penia, and organ failure. 
 Immunosuppression was defined as follows: therapy of pred-
nisolone or an equivalent drug at least 10 mg/day for 15 days, 
and chemotherapy or radiotherapy within 6 months before the 
baseline date. We defined neutropenia as an absolute neutro-
phil count < 1,500 cells/μL blood within 2 weeks before the base-
line date. 
 We investigated invasive procedures, including applications 
of an arterial catheter, abdominal drainage, central venous cath-
eter, ventilator, tracheotomy, hemodialysis, peritoneal dialysis, 
nasogastric tube, thoracic drainage, urinary catheter etc., with-
in 48 hr before the baseline date and the maintenance of any of 
these invasive devices for over 48 hr within 2 weeks before the 
baseline date. 
 Respiratory failure was defined as the condition when PaO2 
< 60 mmHg on FiO2 = 0.2 was observed or when ventilator sup-
port was needed. The condition of systolic arterial pressure < 90 
mmHg with signs of peripheral hypoperfusion or the condition 
of continuous infusion of vasopressors or inotropic agents in 
order to maintain systolic pressure > 90 mmHg was defined as 
cardiovascular failure. Renal failure was described as the condi-
tion of serum creatinine > 300 μM/L or urine output < 500 mL/ 
24 hr or < 180 mL/8 hr or hemodialysis or peritoneal dialysis. 
We defined hepatic failure as serum bilirubin > 100 μM/L or 
alkaline phosphatase > 3 ×  normal.
 We analyzed the history of antibiotic therapy in both case and 
control groups. For this, we investigated the number and type 
of antibiotics used for a period longer than 48 hr within 2 weeks 
before the baseline date. 
 All patients were followed up for 30 days after the onset of 
bacteremia. 
Statistical analyses
Continuous variables were presented as mean ± standard devi-
ation, and comparative analysis was conducted using an inde-
pendent sample t-test. An chi-squared-test and Fisher’s exact 
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test were used for comparative analysis of categorical variables, 
and the odds ratio was calculated with confidence intervals of 
95%. To determine independent risk factors, multivariate anal-
ysis was performed using a logistic regression. Statistical signifi-
cance was defined as P < 0.05. SPSS 17.0 (SPSS, Chicago, IL, USA) 
was used for all analyses.
Ethics statement
This study was approved by the institutional review board of 
Severance Hospital (IRB No. 4-2010-0035). Informed consent 
was waived by the board.
RESULTS
The characteristics of the medical ICU population during the 
study period are as follows: A total of 975 patients were admit-
ted to the ICU and 72 patients were readmitted to the ICU. A 
mechanical ventilator was used in 812 patient during ICU stay. 
Four hundred seventeen patients died during ICU stay. The 
mean age was 61.3 ± 15.6 yr and the number of male patients 
was 618. Major causes of ICU admission are presented in Fig. 1. 
 After excluding readmission, a total of 903 patients were ad-
mitted to the ICU during the research period, and those who died 
within 48 hr after admission to the ICU (n = 208, 23.0%) were 
excluded. In addition, those who showed AB colonization only 
(n = 343, 38.0%) and those who had already had AB coloniza-
tion before admission to the ICU (n = 22, 2.4%) were excluded. 
Those who were transferred from another ICU to the medical 
ICU (n = 15, 1.7%) were also excluded. And those whose blood 
Excluded
Readmission (n = 72)
Excluded
CSAB bacteremia (n = 4)
Excluded
Death < 48 hr (n = 208) 
Colonization before ICU admission (n = 22)
Transferred from another ICU (n = 15)
Colonization (n = 343)
ICU admission during 2008-2009  
(n = 978)
ICU admission excluding readmission  
(n = 903)
No colonization
(n = 315) (34.9%)
CRAB bacteremia
(n = 106)
No colonization 
No bacteremia
(n = 205)
Allergic diseases (n = 1, 0.1%)
Cardiovascular diseases (n = 7, 0.7%) 
Endocrinologic diseases (n = 2, 0.2%) 
Gastroenterologic diseases (n = 182, 18.7%) 
Hematologic diseases (n = 163, 16.7%) 
Infectious diseases (n = 159, 16.9%) 
Nephrologic diseases (n = 72, 7.4%)
Oncologic diseases (n = 83, 8.5%)
Respiratory diseases (n = 294, 30.2%) 
Rheumatologic diseases (n = 12, 1.2%)
Fig. 1. Outline of study design. ICU, intensive care unit; CRAB, carbapenem-resistant Aci-
netobacter baumannii ; CSAB, carbapenem-sensitive Acinetobacter baumannii. 
Table 1. Baseline characteristics of cases and controls 
Parameters
Cases  
(n = 106)
Controls  
(n = 205)
Odds ratio  
(95% CI)
 P value
Age, mean years ± SD 61.8±15.3 60.1±16.2 0.372
Male sex 62 (58.5) 133 (64.9) 0.8 (0.5-1.3) 0.392
Underlying diseases
   Diabetes mellitus
   Chronic lung disease
   Cerebrovascular disease
   Chronic renal disease
   Hypertension
   Cardiovascular disease
   Chronic liver disease
   Rheumatologic disease
   Solid organ malignancy
   Hematologic malignancy
   Transplantation
   HIV infection
 
32 (30.2)
13 (12.3)
12 (11.3)
13 (12.3)
37 (34.9)
13 (12.3)
13 (12.3)
4 (3.8)
29 (27.4)
32 (30.2)
11 (10.4)
2 (1.9)
 
50 (24.4)
21 (10.2)
20 (9.8)
42 (20.5)
74 (36.1)
25 (12.2)
30 (14.6)
13 (6.3)
41 (20.0)
29 (14.1)
10 (4.9)
0 (0)
 
1.3 (0.8-2.2)
1.2 (0.6-2.4)
1.2 (0.6-2.6)
0.5 (0.3-1.0)
1.0 (0.6-1.6)
1.1 (0.5-2.1)
0.9 (0.5-1.8)
0.6 (0.2-1.8)
1.7 (1.0-2.9)
2.5 (1.4-4.4)
2.4 (1.0-5.7)
2.9 (2.5-3.4)
 
0.281
0.668
0.509
0.053
0.910
0.891
0.809
0.311
0.046
0.001
0.062
0.121
Causes of ICU admission
   Infectious diseases
      Respiratory infection
      Genitourinary infection
      Abdominal infection
      CNS infection
      Other infection
      Unknown origin
   Respiratory failure
   Renal failure
   Pulmonary hemorrhage
   Gastrointestinal bleeding
   Hepatic failure
   Cardiologic disease
   Endocrinologic disease
   Others*
  
98 (92.5)
86 (81.1)
6 (5.7)
9 (8.5)
0 (0)
3 (2.8)
2 (1.9)
90 (85.0)
1 (0.9)
1 (0.9)
3 (2.8)
3 (2.8)
2 (1.9)
0 (0)
9 (8.5)
  
148 (72.2)
116 (56.6)
11 (5.4)
23 (11.2)
1 (0.5)
7 (3.4)
9 (4.4)
125 (61.0)
22 (0.7)
3 (1.5)
17 (8.3)
24 (11.7)
19 (9.3)
2 (1.0)
34 (7.3)
  
4.9 (2.2-10.7)
3.5 (2.0-6.0)
1.0 (0.4-2.8)
0.7 (0.3-1.6)
1.5 (1.4-1.7)
0.7 (0.2-3.1)
0.4 (0.1-1.9)
2.9 (1.6-5.0)
0.1 (0.0-0.6)
0.6 (0.1-6.0)
0.3 (0.1-1.1)
0.2 (0.1-0.7)
0.2 (0.0-0.8)
1.5 (1.4-1.7)
0.4 (0.2-1.0)
  
< 0.001
< 0.001
0.974
0.395
0.999
0.740
0.236
< 0.001
0.001
0.999
0.053
0.007
0.012
0.544
0.038
Data are N (%) of patients, unless otherwise indicated. *Others, including brain hem-
orrhage and acute cerebral infarction. CI, confidence intervals; ICU, intensive care 
unit; CNS, central nervous system. 
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culture revealed CSAB (carbapenem-susceptible AB) (n = 4, 0.4%) 
were excluded. After the exclusions, the case group consisted of 
106 patients (11.7%), and the control group included 205 patients 
(22.7%). An outline of the study design is summarized in Fig. 1. 
 Table 1 summarizes the characteristics of the case group and 
control group. There was no significant difference in mean age or 
sex. The prevalence of solid organ malignancy and hematologic 
malignancy was higher in the case group (solid organ malignan-
cy: Odds ratio [OR]: 1.7, P = 0.046; hematologic malignancy: OR, 
2.5, P = 0.001). As to the causes of ICU admission, the percent-
age of respiratory infection and respiratory failure was higher in 
the case group (respiratory infection: OR, 3.5, P < 0.001, respi-
ratory failure: OR, 2.9, P < 0.001). The percentages of those ad-
mitted to the ICU for renal failure, hepatic failure or cardiologic 
disease were lower in the case group than in the control group 
(renal failure: OR, 0.1, P = 0.001, hepatic failure: OR, 0.2, P = 0.007, 
cardiologic disease: OR, 0.2, P = 0.012).
 The univariate analysis of risk factors related to clinical char-
acteristics, recent invasive procedures and presence of invasive 
Table 2. Risk factors for carbapenem-resistant Acinetobacter baumannii bacteremia related clinical characteristics, procedures and presence of devices
Parameters Cases (n = 106) Controls (n = 205) Odds ratio (95% CI) P value
APACHE II scores, mean ± SD   24 ± 15.0 25.8 ± 7.29 0.413
Initial shock status   79 (74.5) 137 (66.8) 1.5 (0.9-2.4) 0.156
GW days before ICU admission 12.0 ± 17.4   4.0 ± 20.3 0.517
ICU hospitalization (days)* 18.7 ± 40.6 9.5 ± 9.4 0.021
Total parenteral nutrition   44 (41.5)    89 (41.5) 1.0 (0.5-1.4) 0.559
Prior chemotherapy or radiotherapy   71 (67.0)    46 (22.4) 6.3 (3.8-10.5) < 0.001
Prior steroid treatment   72 (67.9)    88 (42.9) 1.9 (1.2-3.1) 0.006
Number of antibiotics† 5.2 ± 1.8 3.9 ± 2.0 < 0.001
Neutropenia   24 (22.6)    35 (17.0) 1.4 (0.8-1.5) 0.223
Organ failure 
   Respiratory   93 (87.7)  101 (49.3) 7.7 (4.1-14.6) < 0.001
   Cardiovascular   8 (7.5)    25 (12.2) 0.6 (0.2-1.3) 0.174
   Renal   44 (41.5)    76 (37.0) 1.3 (0.8-2.0) 0.327
   Hepatic   15 (14.2)    28 (13.7) 1.0 (0.5-2.0) 0.996
Invasive procedures ( < 48 hr) 
   Arterial catheter
   Abdominal drainage
   Central venous catheter
   Mechanical ventilator
   Tracheostomy
   Conventional HD & CRRT
   Peritoneal dialysis
   Nasogastric tube
   Thoracic drainage 
   Urinary catheter
   Other procedures‡
 
  5 (4.7)
  18 (17.0)
  67 (63.2)
  6 (5.6)
  3 (2.8)
  32 (30.2)
10 (9.4)
  2 (1.9)
  16 (15.0)
10 (9.4)
  29 (27.3)
 
 11 (5.4)
   3 (1.5)
   26 (12.7)
   9 (4.4)
0 (0)
13 (6.3)
0 (0)
10 (4.9)
   1 (0.5)
 12 (5.9)
   2 (1.0)
 
0.8 (0.3-2.5)
13.2 (3.8-45.8)
10.7 (6.1-18.8)
1.3 (0.4-3.6)
2.9 (2.5-3.4)
4.8 (2.4-9.8)
3.1 (2.6-3.6)
0.4 (0.1-1.7)
34.7 (4.5-265.7)
1.6 (0.7-3.9)
36.3 (8.5-155.8)
 
0.752
< 0.001
< 0.001
0.782
0.042
< 0.001
< 0.001
0.227
< 0.001
0.283
< 0.001
Presence of invasive devices (within 2 weeks)
   Arterial catheter
   Abdominal drainage
   Central venous catheter
   Mechanical ventilator
   Tracheostomy
   Conventional HD & CRRT
   Peritoneal dialysis
   Nasogastric tube
   Thoracic drainage 
   Urinary catheter
   Other procedures‡
 
  97 (91.5)
  5 (4.7)
105 (99.1)
  98 (92.5)
  24 (22.6)
  38 (35.8)
  1 (0.9)
102 (96.2)
  18 (17.0)
103 (97.2)
  4 (3.8)
 
 175 (85.4)
 12 (5.9)
 196 (95.6)
 137 (66.8)
   34 (16.6)
   74 (36.1) 
   6 (2.9)
 176 (85.9)
   21 (10.2)
 188 (91.7)
 19 (9.3)
 
1.3 (0.6-2.6)
0.8 (0.3-2.2)
5.0 (0.6-40.0)
6.3 (2.9-13.8)
1.5 (0.8-2.6)
0.9 (0.6-1.5) 
0.3 (0.0-2.6)
4.4 (1.5-12.8)
1.7 (0.9-3.4)
3.2 (0.9-11.3)
0.4 (0.1-1.1)
 
0.482
0.624
0.093
< 0.001
0.183
0.784
0.036
0.004
0.116
0.053
0.067
Data are No. (%) of patients, unless otherwise indicated. *From ICU admission to bacteremia or ICU discharge; †Received antibiotic therapy for at least 48 hr during 2 weeks 
before bacteremia; ‡Others, including rectal tube and chemoport. CI, confidence intervals; APACHE, acute physiological assessment and chronic health evaluation; GW, general 
ward; ICU, intensive care unit; HD, hemodialysis; CRRT, continuous renal replacement therapy.
Table 3. Multivariate analysis of risk factors related to carbapenem-resistant Acineto-
bacter baumannii bacteremia 
Parameters
Odds ratio  
(95% CI)
 P value
Prior chemotherapy or radiotherapy* 3.6 (1.5-8.3) 0.003
Recent invasive procedure-central venous catheter†   5.7 (2.4-13.6) < 0.001
Recent invasive procedure-abdominal drainage†   21.9 (2.6-181.7) 0.004
Number of antibiotics‡ 1.3 (1.1-1.6) 0.016
Respiratory failure during ICU stay 2.5 (1.1-5.8) 0.035
Data are No. (%) of patients, unless otherwise indicated. *Received chemotherapy or 
radiotherapy 6 months before ICU admission; †Underwent an invasive procedure with-
in 48 hr before bacteremia or ICU discharge; ‡Received antibiotics for at least 48 hr 
within 2 weeks before bacteremia or ICU discharge. CI, confidence intervals; ICU, 
intensive care unit. 
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devices are shown in Table 2. There was no difference in the 
mean APACHE II score and initial shock status for direct ICU 
admission and stay in the general ward before admission to the 
ICU. Stay in the ICU until the baseline date was longer in the case 
group (case group, 18.7 ± 40.6 days vs control group, 9.5 ± 9.4 
days; P = 0.021). Prior chemotherapy or radiotherapy (OR, 6.3; 
P < 0.001), prior steroid treatment (OR, 1.9; P = 0.006), the use 
of many antibiotics for at least 48 hr within the 2 weeks before 
the baseline date (P < 0.001), and respiratory failure in the ICU 
(OR, 7.7; P < 0.001) were also associated with CRAB bacteremia. 
Among procedures conducted within 48 hours before the base-
line date, abdominal drainage (OR, 13.2; P < 0.001), central ve-
nous catheter insertion (OR, 10.7; P < 0.001), tracheotomy (OR, 
2.9; P = 0.042), hemodialysis (OR, 4.8; P < 0.001), peritoneal di-
alysis (OR, 3.1; P < 0.001), and thoracic drainage (OR, 34.7; P <  
0.001) were associated with CRAB bacteremia in the ICU. Among 
invasive devices maintained for over 48 hr within the 2 weeks 
before the baseline date, mechanical ventilators (OR, 6.3; P <  
0.001) and nasogastric tubes (OR, 4.4; P = 0.004) were associat-
ed with CRAB bacteremia in the ICU. 
 Table 3 summarizes the multivariate analysis of risk factors for 
CRAB bacteremia. We identified five independent risk factors 
related with CRAB bacteremia: prior chemotherapy or radio-
therapy in the past (OR, 3.6; P = 0.003), recent central venous 
catheter insertion (OR, 5.7; P < 0.001), recent abdominal drain-
age (OR, 21.9; P = 0.004), the use of many antibiotics for at least 
48 hr within the 2 weeks before the baseline date (OR, 1.3; P =  
0.016), and respiratory failure at the ICU (OR, 2.5; P = 0.035).
 Differences between the two groups in the antibiotics used 
Table 4. Antibiotics usage of before baseline date and upon presentation of CRAB bacteremia 
Antibiotics
Before the baseline date
On the timing of CRAB 
bacteremia
Cases (n = 106) Controls (n = 205) Odds ratio (95% CI) P value Cases (n = 106)
Penicillin
   Antipseudomonal
   Other penicillin
  
64 (60.4)
3 (2.8)
  
101 (49.3)
11 (5.4)
  
1.4 (0.9-2.3)
0.5 (0.1-1.8) 
 
0.131
0.393
 
9 (8.5)
2 (1.9)
Cephalosporin
   1st generation 
   2nd generation 
   3rd generation 
      Ceftazidime
      Others*
   4th generation 
  
2 (1.9)
10 (9.4)
62 (58.5)
38 (35.8)
23 (21.7)
9 (8.5)
  
3 (1.5)
2 (1.0)
99 (48.3)
14 (6.8)
90 (43.9)
15 (7.3)
  
0.6 (0.1-6.0)
10.2 (2.2 -47.2)
1.4 (0.9-2.2)
7.2 (3.7-14.1)
0.3 (0.2-0.6)
1.1 (0.5-2.7)
 
0.999
< 0.001
0.172
< 0.001
< 0.001
0.783
 
0 (0)
0 (0)
15 (14.2)
11 (10.4)
4 (3.8)
2 (1.9)
Fluoroquinolone 51 (48.1) 99 (48.3) 0.9 (0.6-1.5) 0.744 18 (17.0)
Carbapenem 85 (80.2) 112 (54.6) 2.8 (1.7-4.8) < 0.001 80 (75.5)
Glycopeptide 61 (57.5) 123 (60.0) 0.8 (0.5-1.3) 0.435 69 (65.1)
Aminoglycoside 27 (25.5) 31 (15.1) 1.8 (1.0-3.3) 0.040 10 (9.4)
Anti-anaerobic antibiotic 28 (26.4) 79 (38.5) 0.5 (0.3-0.9) 0.019 29 (27.4)
Macrolide 16 (15.1) 12 (5.9) 2.7 (1.2-6.0) 0.010 3 (2.8)
Antifungal agents 29 (27.4) 48 (23.4) 1.2 (0.7-2.0) 0.562 46 (43.4)
Antiviral agents 37 (35.0) 23 (11.2) 4.0 (2.2-7.2) < 0.001 27 (25.5)
TMP-SMX 55 (51.9) 25 (12.2) 7.2 (4.1-12.6) < 0.001 46 (43.4)
Colistin 12 (11.3) 10 (4.9) 2.4 (1.0-5.7) 0.045 8 (7.5)
Others† 31 (29.2) 22 (10.7) 3.3 (1.8-6.0) < 0.001 14 (14.2)
Data are No. (%) of patients, unless otherwise indicated. *Others, including ceftriaxone, cefperazone-sulbactam and cefotaxime; †Others, including doxycycline, synercid, zyvox 
and tygacil. CI, confidence intervals; CRAB, carbapenem-resistant Acinetobacter baumannii , TMP-SMX, Trimethoprim-sulfamethoxazole.
Table 5. Risk factors for 30-day mortality in carbapenem-resistant Acinetobacter 
baumannii bacteremia
Parameter
Non- 
survivor 
(n = 79)
Survivor 
(n = 20)
Odds ratio  
(95% CI)
P value
Age, mean years ± SD 59.8 ± 15.7 68.3 ± 8.9 0.003
Male sex 45 (57.0) 13 (65.0) 0.7 (0.3-2.0) 0.514
Underlying diseases
   Diabetes mellitus
   Chronic lung disease
   Cerebrovascular disease
   Chronic renal disease
   Hypertension
   Cardiovascular disease
   Chronic liver disease
   Rheumatologic disease
   Solid organ malignancy
   Hematologic malignancy
   Transplantation
   HIV infection
 
23 (29.1)
7 (8.9)
6 (7.6)
  8 (10.1)
28 (35.4)
7 (8.9)
13 (16.5)
4 (5.1)
22 (27.8)
28 (35.4)
  9 (11.4)
2 (2.5)
 
   8 (40.0)
5 (25)
4 (20)
   5 (25.0)
   8 (40.0)
   3 (15.0)
     0 (0)
     0 (0)
   4 (20.0)
   3 (15.0)
   2 (10.0)
 0 (0.0)
 
0.6 (0.2-1.7)
0.3 (0.1-1.0)
0.3 (0.1-1.3)
0.3 (0.1-1.2)
0.8 (0.3-2.3)
0.6 (0.1-2.4)
0.8 (0.7-0.9)
0.8 (0.7-0.9)
1.5 (0.5-5.1)
3.1 (0.8-11.5)
1.2 (0.2-5.8)
0.8 (0.7-0.9)
 
0.348
0.048
0.206
0.079
0.705
0.418
0.065
0.580
0.578
0.106
1.000
1.000
Shock status at admission 57 (72.2)  16 (80.0) 0.6 (0.2-2.2) 0.578
APACHE II scores 
   at admission, mean ± SD
24.4 ± 8.5 23.5 ± 6.0 0.587
Neutropenia 22 (27.8)  1 (5.0) 7.3 (0.9-58.1) 0.037
Organ failure 
   Respiratory
   Cardiovascular
   Renal 
   Hepatic 
 
71 (89.9)
7 (8.9)
39 (49.4)
13 (16.5)
 
 15 (75.0)
 1 (5.0)
   4 (20.0)
   2 (10.0)
 
3.0 (0.8-10.3)
1.8 (0.2-16.0)
3.9 (1.2-12.7)
1.8 (0.4-8.6)
 
0.079
1.000
0.023
0.729
Data are No. (%) of patients, unless otherwise indicated. CI, confidence intervals; 
APACHE, acute physiological assessment and chronic health evaluation.
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before the baseline date are presented in Table 4. The percent-
age of those who used 2nd generation cephalosporin (P < 0.001), 
ceftazidime (P < 0.001), carbapenem (P < 0.001), aminoglyco-
side (P = 0.040), macrolide (P = 0.010), antiviral agents (P <  
0.001), trimethoprim-sulfamethoxazole (P < 0.001), and colis-
tin (P = 0.045) was higher in the case group than in the control 
group. We also analyzed antibiotic administration at the time of 
CRAB bacteremia presentation. Carbapenem (75%), glycopep-
tides (65.1%), antifungal agents (43.4%), and trimethoprim-sul-
famethoxazole (43.4%) were commonly administered upon pre-
sentation of CRAB bacteremia. 
 Antimicrobial resistance patterns of CRAB were also analyzed. 
Most cases were resistant to almost all antibiotics tested except 
for colistin (0%), minocycline (5%), and rifampin (15.4%).  
 Table 5 shows the risk factors for 30-day mortality in CRAB 
bacteremia patients. The 30-day mortality was 79.8% (79/99). 
Patients who had a poor outcome were younger in mean age 
(Non-survivor 59.8 ± 15.7 yr vs Survivor 68.3 ± 8.9 yr) and had 
lower prevalence of chronic lung disease (OR, 0.3; P = 0.048). 
However, this difference was not significant in the logistic re-
gression analysis. Univariate analysis showed that neutropenia 
(OR, 7.3; P = 0.037) and renal failure (OR, 3.9; P = 0.023) during 
ICU stay were significant risk factors for mortality. In the multi-
variate analysis, only renal failure during ICU stay was indepen-
dently associated with 30-day mortality (OR, 3.7; P = 0.047).
 As we applied the activities for reducing CRAB infection for 
1 yr, which were monitoring of hand washing, sooner removal 
of invasive devices, closed suction catheter use and by applying 
maximal barrier precautions upon device insertion, the num-
ber of patients with CRAB bacteremia has been decreasing since 
July 2010 (Fig. 2).
 
DISCUSSION
We attempted to identify risk factors for CRAB bacteremia and 
for 30-day mortality in patients with CRAB bacteremia through 
a retrospective case-control study. We also analyzed antibiotic 
usage patterns and antimicrobial resistance patterns in CRAB 
bacteremia patients.
 Chemotherapy or radiotherapy within 6 months before ad-
mission to the ICU was found to be a risk factor for CRAB bac-
teremia, and this was consistent with previous studies (13). The 
fact that the probability of CRAB bacteremia increases in immu-
nocompromised patients reflects the opportunistic character-
istic of AB infections.
 Respiratory failure after admission to the ICU was another 
risk factor for CRAB bacteremia, and this was consistent with 
the results of some previous studies (13). This was reasonable, 
given the previous reports that respiratory failure accelerates 
respiratory AB colonization and AB colonization is a risk factor 
for AB bacteremia (22). Respiratory failure was reliable risk fac-
tor for CRAB bacteremia, because secondary AB bacteremia 
generally begins with respiratory infection (28, 29). Hence, the 
use of a ventilator was also shown to be a risk factor of AB colo-
nization and infection.
 In our results, recent central venous catheter insertion increased 
the incidence of CRAB bacteremia and this result is likely relat-
ed to the severe status in patients with central venous catheter. 
Although there was no differences in APACHE II scores, the fact 
that stay in the ICU was longer in the case group than in the con-
trol group (case: 18.7 ± 40.6 days vs control: 9.5 ± 9.4 days, P <  
0.021) suggests that severity might have increased in the case 
group was prolonged after ICU admission. 
 Recent abdominal drainage increased the incidence of CRAB 
bacteremia, but this result has never been reported in previous 
studies. Because most abdominal drainage cases are for percu-
taneous transhepatic biliary drainage in order to treat biliary 
infection or for abscess drainage in the abdominal cavity, this 
result might be related to frequent treatment of severe diseases. 
Or this might be due to AB colonization in the skin of patients, 
on the hands of doctors, or in the materials that potentially cause 
abdominal vessel injury during abdominal drainage catheter 
insertion. From the culture of external environments of patients, 
AB from the environment and from the patients’ blood was con-
cordant by finger print polymerase chain reactions (Fig. 3). Thus, 
a mechanism of infection by which frequent procedures and 
colonization of the skin of patients causes CRAB bacteremia is 
not unreasonable. Because the number of patients who under-
went abdominal drainage was small in each group (18 in the case 
group vs 3 in the control group) and we did not screen for colo-
nization of the skin of patients or hands of doctors, additional 
study is necessary for validation of the proposed mechanism.
 The risk of CRAB bacteremia increased when the number of 
antibiotics recently administered became larger. In addition, 
there were differences between the two groups in the types of 
antibiotics used. More frequent use of aminoglycoside in the 
case group was consistent with previous reports (22). Ceftazi-
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Fig. 2. Trends of incidence of CRAB bacteremia after 1 yr of CRAB reduction activity. 
CRAB, carbapenem-resistant Acinetobacter baumannii ; ICU, intensive care unit. 
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dime and colistin, which are often used against multidrug resis-
tant strains, were also used in the case group more frequently. 
Thus, our results suggest that there was a preceding or accom-
panying infection by resistant strains other than CRAB. The fre-
quent use of trimethoprim-sulfamethoxazole and antiviral agents 
was considered to be related with the immunosuppressive char-
acteristic of the patients in the case group. From the analysis of 
antibiotics administered upon presentation of CRAB bactere-
mia, the common use of carbapenem could be related to the 
occurrence of CRAB. The frequent use of glycopetide, antifun-
gal agents, or trimethoprim-sulfamethoxazole might be due to 
the immunosuppressive or severely infectious characteristics of 
the patients. We also analyzed antimicrobial resistance rates in 
the case group. Most cases were resistant to almost all antibiot-
ics tested except for colistin (0%), minocycline (5%), or rifampin 
(15.4%). This could be related to frequent antibiotic usage. 
 We revealed that renal failure during ICU stay was an inde-
pendent risk factor for 30-day mortality in patients with CRAB 
bacteremia. As other studies did not address renal failure dur-
ing ICU stay, this was a new finding to which there was nothing 
to compare.
 During the study period, between July 2008 and December 
2009, the number of patients with CRAB bacteremia in the ICU 
did not decrease. After conducting surveillance culture of the 
environment, including beds and mechanical ventilators, 32 
isolates (30.4%) of AB were screened among the 105 specimens. 
By finger print polymerase chain reactions for AB cultured from 
the environment and from the patients’ blood, the concordance 
of type was confirmed. We have since tried to control CRAB bac-
teremia by monitoring hand washing, sooner removal of inva-
sive devices, closed suction catheter use and applying maximal 
barrier precautions upon device insertion including hand wash-
ing, wearing a cap, masks, sterile gowns and gloves for the oper-
ators and covering from head to toe with sterile drapes for the 
patients (30). After 1 yr, with the introduction of these CRAB re-
ducing activities, the number of patients with CRAB bacteremia 
has been decreasing since July 2010. These results are similar 
with a previous study which demonstrated that contact precau-
tions, environmental decontamination, and a use of a closed-
suction system could be beneficial for controlling CRAB out-
break (31). 
 This study has several limitations. First, as this study was con-
ducted retrospectively, it might have selection bias based on the 
condition of different ICUs. Second, some previous studies re-
ported matching selection of the control group for certain vari-
ables, but this study did not match the control group. The match-
ing process would be useful in limiting selection bias, consider-
ing the period until AB bacteremia in the case group patients 
was certainly longer than whole ICU stay of patients in the con-
trol group. However, we could not perform the matching pro-
cess because the number of control patients was relatively small. 
Nevertheless, this limitation could be overcome because there 
were no significant differences between the two groups in age, 
sex and APACHE II score. Third, we excluded CRAB-colonized 
patients although the colonization of CRAB can influence other 
risk factors, but the timing of the colonization may be inaccurate 
as regular active surveillance was not performed. We excluded 
CRAB-colonized patients from the case and control groups, 
because we tried to identify risk factors other than colonization 
of CRAB through this design. However, future study including 
CRAB-colonized patients will be needed as the colonization of 
CRAB can influence other risk factors. Fourth, this study was 
conducted in a single center, so the results may be different ac-
cording to the settings of different ICUs.
 Nevertheless, this study is meaningful in that it analyzed a 
relatively large number of patients (n = 106) and identified risk 
factors for CRAB bacteremia comprehensively and extensively 
by investigating most of the variables found in previous studies. 
Especially, we focused on antibiotics usage and antimicrobial 
resistance. We also analyzed risk factors related to 30-day mor-
Fig. 3. Finger print polymerase chain reactions of CRAB from patients (A) and the ICU environment (B). CRAB, carbapenem-resistant Acinetobacter baumannii ; ICU, intensive 
care unit. 
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tality. By these results, we can understand more about CRAB 
bacteremia. Because CRAB infection has only recently emerged 
as an issue in Korea, it is also important that this was the first 
study addressing CRAB bacteremia in Korea. Moreover, as AB 
colonization is known to be an important risk factor of AB bac-
teremia (22), those who had AB colonization were excluded from 
analysis. This stipulation led to a more accurate and efficient 
analysis for identifying risk factors other than AB colonization.
 In conclusion, prior chemotherapy or radiotherapy, recent 
central venous catheterization, recent abdominal drainage, a 
large number of antibiotics used, and respiratory failure during 
ICU stay are independent risk factors for CRAB bacteremia. Re-
nal failure during ICU stay is the only risk factor independently 
associated with 30-day mortality. It is important to prevent ven-
tilator-associated pneumonia caused by CRAB in immunosup-
pressive patients in the ICU and to minimize invasive procedures 
and excessive use of antibiotics to prevent the development of 
CRAB bacteremia. Also, greater concern for CRAB bacteremia 
patients is needed when renal failure develops during ICU stay.
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